15th Annual Oncology Spring Forum

Emerging Concepts in Cancer Care







Saturday, April 27, 2019 7:45 am - 4:30 pm

Westwood Conference Center 1800 Westwood Center Blvd Wausau, WI 54401









Intended Audience

This conference is designed for individuals who are involved in cancer treatment and education of cancer patients: physicians, pharmacists, nurses, radiation therapists, medical dosimetrists, nurse practitioners, clinical research associates, health educators, social workers, psychologists, cancer registry professionals and other interested health care professionals involved in cancer care.

Learning Objectives/Purpose

This conference is designed to educate and prepare health care professionals in issues relating to the treatment of cancer patients.

At the end of this activity, participants should be able to:

- 1. Describe the surgical technique in a Mohs procedure, including the role of pathology, and identify the impact that the Mohs procedure has on cancer therapy.
- 2. Review the evolution of the use of radiation therapy in Hodgkin and non-Hodgkin lymphoma and discuss the current role of radiation therapy in early and advanced stages of lymphoma.
- 3. Define treatment sequencing and its role in pancreatic cancer.
- 4. Explain the pathology and staging of GI neuroendocrine tumors (NET) and discuss pharmacologic intervention and the role of radiation therapy in treating GI NET.
- 5. Review the basic approach and decision making involved in the resection and reconstruction for cancers of the head and neck.
- 6. Review the current therapies that are being used for relapsed/refractory multiple myeloma, including emerging therapies.
- 7. Review the updates within the AJCC 8th Edition breast cancer staging guidelines and discuss how staging changes may affect emerging therapies and utilization of radiation.
- 8. Review USP 800 and USP 797 guidelines and discuss changes in practice for nursing, pharmacy, radiation, environmental services, and other healthcare workers in the handling of hazardous and cytotoxic agents.

Date/Time/Location

Saturday, April 27, 2019

Registration: 7:15 am - 7:45 am **Program:** 7:45 am - 4:30 pm

Westwood Conference Center, 1800 Westwood Center Boulevard, Wausau, WI 54401

Westwood Conference Center is an accessible, barrier-free location.

Please contact Mary Kay Dreikosen at 715.847.2429 if you require any special accommodations. A link to access the PowerPoint presentations will be sent via email prior to the conference.

Planning Committee Members

Anne Cejka, RN, OCN Rhonda Nousen, BS, RTT, RTR Jody Tarkowski, MSN, RN Heidi Somsen, MHA Lisa Opatik, PharmD **Denise Vanderkooy,** RTT, CMD **Jessica Marshall,** PharmD **Amber Sopata,** MSN, RN, CNL **Michelle Westpfahl,** BS, RTT **Juli Alford,** RN, OCN Mary Kay Dreikosen Christopher Peterson, MD Samantha Reynolds, CTR

Conference Agenda

7:15 - 7:45 am	Registration/Continental Breakfast/Vendor Exhibits
7:45 - 8:00 am	Welcome Christopher Peterson, MD
8:00 - 8:50 am	Update on the Management of Relapsed or Refractory Myeloma Parameswaran Hari, MBBS, MD, MRCP, MS – Chief, Division of Hematology Oncology Department of Medicine, Medical College of Wisconsin, Milwaukee, WI
8:50 - 9:40 am	Modern Radiotherapy for Lymphomas Christopher Platta, MD – Radiation Oncologist Aspirus Regional Cancer Center, Wausau, WI
9:40 - 10:10 am	Break
10:10 - 11:00 am	Treatment and Sequencing of Localized Pancreatic Cancer Ben George, MD – Assistant Professor Cancer Center-Froedtert Hospital, Milwaukee, WI
11:00 - 11:50 am	Advances in Treating GI Neuroendocrine Tumors Sam Lubner, MD, FACP – Assistant Professor University of Wisconsin Carbone Comprehensive Cancer Center, Madison, WI
11:50 am - 12:45 pm	Lunch
12:45 - 1:35 pm	Surgical Management and Reconstruction for Head and Neck Cancer Gregory Hartig, MD, FACS – Chief, Head and Neck Oncology, Division of Otolaryngology – Head and Neck Surgery University of Wisconsin, Madison, WI
	Surgical Management and Reconstruction for Head and Neck Cancer Gregory Hartig, MD, FACS – Chief, Head and Neck Oncology, Division of Otolaryngology – Head and Neck Surgery
12:45 - 1:35 pm	Surgical Management and Reconstruction for Head and Neck Cancer Gregory Hartig, MD, FACS – Chief, Head and Neck Oncology, Division of Otolaryngology – Head and Neck Surgery University of Wisconsin, Madison, WI The Role of Moh's Surgery in the Treatment of Skin Cancers Agnieszka Thompson, MD – Dermatologist
12:45 - 1:35 pm 1:35 - 2:25 pm	Surgical Management and Reconstruction for Head and Neck Cancer Gregory Hartig, MD, FACS – Chief, Head and Neck Oncology, Division of Otolaryngology – Head and Neck Surgery University of Wisconsin, Madison, WI The Role of Moh's Surgery in the Treatment of Skin Cancers Agnieszka Thompson, MD – Dermatologist Aspirus Dermatology Clinic, Wausau, WI
12:45 - 1:35 pm 1:35 - 2:25 pm 2:25 - 2:40 pm	Surgical Management and Reconstruction for Head and Neck Cancer Gregory Hartig, MD, FACS – Chief, Head and Neck Oncology, Division of Otolaryngology – Head and Neck Surgery University of Wisconsin, Madison, WI The Role of Moh's Surgery in the Treatment of Skin Cancers Agnieszka Thompson, MD – Dermatologist Aspirus Dermatology Clinic, Wausau, WI Break AJCC Staging Guidelines for Breast Cancer and the Implications for Treatment Amanda Parkes, MD – Assistant Professor

Registration and Fees

PRE-REGISTRATION IS REQUIRED; REGISTRATION IS LIMITED.

Employees and providers of Aspirus, Inc. and Aspirus-affiliated organizations: Registration is available through HealthStream. There is no charge, but a \$25 fee will be assessed for no shows and cancellations after April 23, 2019.

All other attendees: Registration is available online at <u>aspirus.org/oncologyconference</u>. Cost is \$25 and Visa, MasterCard and Discover are accepted. Refunds will not be granted.

Registration available online at <u>aspirus.org/oncologyconference</u> or via HealthStream.

If paying by check make payable to Aspirus Regional Cancer Center and mail to:

Aspirus Regional Cancer Center
Attn: Mary Kay Dreikosen
215 N. 28th Ave.
Wausau, WI 54401

Disclosure

It is the policy of Aspirus, Inc. and Aspirus Regional Cancer Center that the faculty and sponsor disclose any real or apparent conflict of interest relating to the topics of this educational activity. They are also required to disclose discussions or unlabeled/unapproved uses of drugs or devices during their presentation(s). Detailed disclosure will be made in the course handout materials.

Continuing Education

Statement of Accreditation

Aspirus, Inc. is accredited by the Wisconsin Medical Society to provide continuing medical education for physicians.

Credit Designation Statement

Aspirus, Inc. designates this live activity for a maximum of 7.0 AMA PRA Category 1 Credits™. Physicians should claim only the credit commensurate with the extent of their participation in the activity.

Credit Designation Statement

8 continuing education credits for ARRT & MDCB have been applied for.

Continuing Nursing Education

Aspirus, Inc. is an approved provider of continuing nursing education by the Wisconsin Nurses Association, an accredited approver by the American Nurses Credentialing Center's Commission on Accreditation. Participants must attend the entire program and complete the evaluation in order to receive contact hours. This program awards 6.66 contact hours. No partial credit will be awarded.

ILNA

ILNA coding has been approved by ONCC and will be provided upon arrival.

Pharmacist Learning Objectives

At the end of this activity, participants should be able to:

- Explain the advantages and disadvantages of radiation therapy and how it affects surgical outcomes for patients with head and neck cancers.
- 2. Discuss how breast cancer staging changes may affect emerging therapies and utilization of radiation.
- 3. Review the current therapies being used for relapsed/refractory multiple myeloma, including emerging therapies.
- 4. Discuss the risks and complications related to Moh's surgery and describe management of complications, including pharmacologic interventions.
- 5. Discuss the use of pharmacologic agents to help mitigate symptoms of acute toxicity from radiation therapy.
- 6. Review USP 800 and USP 797 guidelines and the changes in practice for nursing, pharmacy, radiation, and other healthcare workers.
- 7. Discuss the pharmacologic treatment options for neuroendocrine tumors.
- 8. Define treatment sequencing and its role in pancreatic cancer.

Pharmacy Continuing Education Requirements

This activity is structured to meet knowledge-based educational needs. A knowledge-based activity acquires factual knowledge. Information in knowledge-based activities is based on evidence as accepted in the literature by the health care professions. Pharmacy continuing education (PCE) credit will be earned based on participation in this activity. Any individual who is more than 10 minutes late to an activity or leaves an activity early will not be granted PCE credit. This procedure will be strictly enforced, so please plan accordingly.

Participants must fully participate in the activity and complete an online activity evaluation and posttest questions, if received by presenters, with a passing score of 70 percent or greater before May 11, 2019. Online evaluations and posttests will not be available for completion and requests to process credit will not be accepted after this date. See the program instruction sheet distributed during the activity for the online activity link. Posttests will not be graded and

credit will not be processed until the online evaluation and posttest has officially closed for response. Please allow MPA two weeks to grade posttests and process and upload credit to CPE Monitor after the evaluation and posttest has closed. NOTE: ACPE guidelines prohibit MPA from issuing credit more than 60 days after the activity for any reason; therefore, to avoid denial of credit, it is imperative that pharmacists and pharmacy technicians complete the online evaluation and posttest by the deadline indicated to allow sufficient time for processing. If all requirements are met, participants will receive pharmacy continuing education (PCE) credit through CPE Monitor, a national, collaborative effort by ACPE and the National Association of Boards of Pharmacy (NABP) to provide an electronic system for pharmacists and pharmacy technicians to track their completed PCE credits. MPA, as an ACPE-accredited provider, is required to report pharmacist and pharmacy technician PCE credit using this tracking system. Pharmacist and pharmacy technician participants must provide their NABP e-Profile identification number and date of birth (in MMDD format) when they complete activity evaluations. It will be the responsibility of the participant to provide the correct information. If this information is not correctly provided, NABP and ACPE prohibit MPA from issuing CPE credit. Online access to their inventory of completed credits will allow pharmacists and pharmacy technicians to easily monitor their compliance with CPE requirements and print statements of credit. Therefore, MPA will not provide printed statements of credit to pharmacists and pharmacy technicians. Partial credit will not be awarded. If you have yet to sign up for CPE Monitor, go to MyCPEMonitor.net.

ACPE Universal Activity Program #0112-9999-19-339-L04-P

6.5 contact hours

Knowledge-based Activity

Initial Release Date: 04/27/2019; Expiration Date: 04/27/2020



Michigan Pharmacists Association is accredited by the Accreditation Council for Pharmacy Education (ACPE) as a provider of continuing pharmacy education.

